Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496659 | 0.81 | HDAC11 (0.62) | ALDH1A1HDAC11NPC1RAB9AKMT2A | |
| SCHEMBL21496671 | 0.78 | TRAP1 (0.50) | TRPA1ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL6093402 | 0.77 | MEN1 (0.52) | TRPA1ALDH1A1LMNAMAPK1KMT2A | |
| SCHEMBL21500485 | 0.76 | TRPA1 (0.43) | TRPA1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL25932303 | 0.76 | HDAC11 (0.53) | TRPA1HDAC11NPC1RAB9AKMT2A | |
| SCHEMBL28320898 | 0.75 | TRPA1 (0.44) | TRPA1ALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL29663126 | 0.75 | TRPA1 (0.44) | TRPA1ALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL15565220 | 0.74 | KDM4E (0.51) | TRPA1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL2061459 | 0.74 | RAB9A (0.58) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL11855241 | 0.73 | TRPA1 (0.60) | TRPA1ALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112292370-A | Isoindolines as HDAC inhibitors | 瓦洛早期发现股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | TRPA1 3565/4885ALDH1A1 1182/4885LMNA 1250/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | TRPA1 3637/4885ALDH1A1 1133/4885LMNA 1180/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | TRPA1 3565/4885ALDH1A1 1182/4885LMNA 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.